The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice

PLoS One. 2013 Jul 16;8(7):e69193. doi: 10.1371/journal.pone.0069193. Print 2013.

Abstract

Seleno-organic glutathione peroxidase (GPx) mimetics, including ebselen (Eb), have been tested in in vitro studies for their ability to scavenge reactive oxygen and nitrogen species, including hydrogen peroxide and peroxynitrite. In this study, we investigated the efficacies of two Eb analogues, m-hydroxy ebselen (ME) and ethanol-ebselen (EtE) and compared these with Eb in cell based assays. We found that ME is superior in attenuating the activation of hydrogen peroxide-induced pro-inflammatory mediators, ERK and P38 in human aortic endothelial cells. Consequently, we investigated the effects of ME in an in vivo model of diabetes, the ApoE/GPx1 double knockout (dKO) mouse. We found that ME attenuates plaque formation in the aorta and lesion deposition within the aortic sinus of diabetic dKO mice. Oxidative stress as assessed by 8-OHdG in urine and nitrotyrosine immunostaining in the aortic sinus and kidney tubules, was reduced by ME in diabetic dKO mice. ME also attenuated diabetes-associated renal injury which included tubulointerstitial fibrosis and glomerulosclerosis. Furthermore, the bioactivity of the pro-fibrotic cytokine transforming growth factor-β (TGF-β) as assessed by phospho-Smad2/3 immunostaining was attenuated after treatment with ME. TGF-β-stimulated increases in collagen I and IV gene expression and protein levels were attenuated by ME in rat kidney tubular cells. However, in contrast to the superior activity of ME in in vitro and cell based assays, ME did not further augment the attenuation of diabetes-associated atherosclerosis and renal injury in our in vivo model when compared with Eb. In conclusion, this study strengthens the notion that bolstering GPx-like activity using synthetic mimetics may be a useful therapeutic strategy in lessening the burden of diabetic complications. However, these studies highlight the importance of in vivo analyses to test the efficacies of novel Eb analogues, as in vitro and cell based assays are only partly predictive of the in vivo situation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins E / deficiency*
  • Apolipoproteins E / genetics
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Azoles / chemistry
  • Azoles / therapeutic use*
  • Cell Line
  • Diabetes Mellitus, Experimental
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Glutathione Peroxidase / deficiency*
  • Glutathione Peroxidase / genetics
  • Humans
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / therapeutic use
  • Isoindoles
  • Male
  • Mice
  • Mice, Knockout
  • Models, Chemical
  • Organoselenium Compounds / chemistry
  • Organoselenium Compounds / therapeutic use*
  • Rats

Substances

  • Apolipoproteins E
  • Azoles
  • Hypoglycemic Agents
  • Isoindoles
  • Organoselenium Compounds
  • ebselen
  • Glutathione Peroxidase

Grants and funding

SMT is supported by a Juvenile Diabetes Research Foundation International Postdoctoral Fellowship. JBdH is supported by National Health and Medical Research Council Grant (#526656) and Baker IDI Medicinal Chemistry Grant. This study was supported in part by the Victorian Government’s OIS Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.